lifestyle.californiaconsumerbanking.com

Author: Zhongshan Kangfang Biological Medicine Co., LTD

All Approved Indications of Five Akeso’s Innovative Drugs Included in China’s Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

December 7, 2025
Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer’s Disease Clinical Trials in China

November 19, 2025